search
Back to results

Effects of Ethanol on the Pharmacokinetics of PT-150 (Formerly ORG34517) (PT150 PK Study)

Primary Purpose

Potential Treatment for Alcohol Dependence-Alcohol Interaction

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
PT150
Beverage
Sponsored by
Pop Test Oncology LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Potential Treatment for Alcohol Dependence-Alcohol Interaction focused on measuring Alcohol, Alcoholic, Alcoholism, Alcohol abuse, Alcohol interaction, Alcohol Use Disorder, Alcohol use, Alcohol dependence, Alcohol dependent, Post Traumatic Stress Disorder, Substance use Disorder, Ethanol abuse, Ethanol use, Pharmacokinetics

Eligibility Criteria

21 Years - 64 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Provide signed and dated informed consent form;
  2. Male or female, aged 21-64;
  3. Must score < 10 on the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar) assessed in the context of a BAL ≤ 0.00% to demonstrate that they do not need medical detoxification;
  4. Must have blood lab test results within the acceptable limits noted in the protocol (Tests may be repeated if initial results are out of range);
  5. Have normal vitals (heart rate 50-100 bpm, systolic blood pressure 90-140 mmHg and diastolic blood pressure 60-90 mmHg) and a baseline ECG that demonstrates clinically normal sinus rhythm, clinically normal conduction, normal QTc, and no clinically significant arrhythmias;
  6. Have a self-reported medical history and brief physical examination demonstrating no clinically significant contraindications for study participation, in the judgment of the admitting physician;
  7. Must be willing to comply with all study procedures and be available for the duration of the study;
  8. Women must either be unable to conceive (i.e., surgically sterilized, sterile, or post-menopausal) or using non-hormonal, medically acceptable contraception during the study and for at least 2 weeks after study completion, with or without additional hormonal contraception. Women can be receiving hormone replacement treatment (HRT) as long as the HRT dose has been stable for a period of at least 3 months;
  9. Women must provide a negative urine pregnancy test within 30 days of alcohol administration on Day 1/baseline (i.e. during the screening period) and a negative serum pregnancy test on day 1 prior to alcohol administration and on day 5. Note that because participants are supervised 24-hours a day when they reside as inpatients, a urine pregnancy test is planned on day 7;
  10. Able to provide proof of age and identity (includes providing full name and date of birth).

Exclusion Criteria:

  1. DSM-5 criteria for substance use disorders other than alcohol or nicotine or test positive for prescription or illegal substances. With regard to marijuana/THC, an individual must test negative at intake (Day 1/baseline). If an individual tests positive, they will be given a grace period where they will have the opportunity to return and test negative prior to being enrolled;
  2. Be pregnant or nursing;
  3. Be receiving HRT where their dose has not been stable for a minimum of 3 months;
  4. To reduce variability in the magnitude of drug-drug interactions (DDIs), use of concomitant medications (except birth control pills) or OTC medications should be excluded for a sufficient time before subject enrollment (at least 14 days or 5 half-lives [whichever is longer]) and for the entire duration of the study. These items should be excluded for a longer time period if the DDI mechanism is induction or time-dependent inhibition. Concomitant medication use includes any prescription, over-the-counter medications or dietary/herbal/nutritional supplements;
  5. Be receiving any non-pharmacotherapy treatments or procedures for which there are precautions for taking concomitantly with PT150 and/or those that might interfere with the study;
  6. Have neurological or psychiatric disorders other than AUD;
  7. History of suicide attempts and/or current suicidal ideation/plan;
  8. Have evidence of untreated or unstable medical illness including: cardiovascular, neuroendocrine, autoimmune, renal, hepatic, or active HIV+, AIDS infection;
  9. Have a history of medically adverse reactions to alcohol (e.g., loss of consciousness (LOC), chest pain, or epileptic seizure) or major alcohol-related medical complications requiring hospitalization (i.e. hepatitis or pancreatitis);
  10. Have contraindication(s) to take the study medications such as renal or hepatic impairment, congenital metabolic disorders, or hypersensitivity to study medication class (i.e., glucocorticoid antagonists);
  11. Have past brain injury/head trauma with current symptoms (e.g. not photophobic, dizziness, etc.) or past report of LOC for >30 minutes and/or have been blast-exposed or had LOC of >1 minute and current post-concussive symptoms;
  12. Self-report more than thirty days' abstinence from alcohol during the three months prior to enrollment/consent;
  13. Current signs of violence or aggression assessed as part of the consent process;
  14. Participation in a pharmaceutical trial or exposure to investigational drugs within 1 month of the screening visit;
  15. Be currently seeking treatment for AUD;
  16. Have any other illness, condition, or use medications (psychotropic or antiretroviral), which in the opinion of the PI and/or the admitting physician would preclude safe and/or successful completion of the study;
  17. A history of adrenal insufficiency or a baseline plasma cortisol level of ≤ 5mcg/dL;
  18. A baseline cortisol of > 5 mcg/dL BUT a post-ACTH stimulation cortisol of <18 mcg/dL;
  19. Have been treated with any form of corticosteroid in the past 30 days;
  20. Have a history of endometrial hyperplasia, endometrial cancer, uterine polyps, or unexplained vaginal bleeding;
  21. Have potassium levels below the normal reference range;
  22. Men taking testosterone replacement therapy;
  23. Men or women currently interested in fertility;
  24. Have underlying inflammatory or auto-immune disorders;
  25. Have elevated thyroid stimulating hormone (TSH) levels;
  26. Have diabetes.

Sites / Locations

  • Michael E. DeBakey Veterans Affairs Medical CenterRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

PT150 with alcohol consumption

Arm Description

Study drug to be administered as a single, fixed dose over a 5-day period. An alcohol challenge will be completed on day 1 (pre-treatment) followed by blood draws over a 24-hour period. PT150 dosing will begin on study day 2 and continue until steady state is reached on day 6, at which point blood draws will occur over a 24-hour period. On day 7, after PT150 steady state has been achieved, an alcohol challenge will be completed followed by blood draws over a 40-hour period.

Outcomes

Primary Outcome Measures

Difference in maximum concentration of PT150 (CmaxPT150)
Estimates of maximum concentration (Cmax) of PT150 will be calculated and compared from PT150 steady state alone (days 6-7) to concurrent steady state of PT150 with ethanol exposure (days 7-9).
Difference in time of maximum concentration of PT150 (tmaxPT150)
Estimates of time of maximum concentration (Tmax) of PT150 will be calculated and compared from PT150 steady state alone (days 6-7) to concurrent steady state of PT150 with ethanol exposure (days 7-9).
Difference in terminal elimination half-life of PT150 (t1/2PT150)
Estimates of terminal elimination half-life (T1/2) of PT150 will be calculated and compared from PT150 steady state alone (days 6-7) to concurrent steady state of PT150 with ethanol exposure (days 7-9).
Difference in area under the concentration-time curve of PT150 (AUCPT150)
Estimates of the area under the concentration curve (AUC) through 24 hours post-intervention of PT150 will be calculated and compared from PT150 steady state alone (days 6-7) to concurrent steady state of PT150 with ethanol exposure (days 7-9).

Secondary Outcome Measures

Difference in the maximum concentration of ethanol (CmaxEtOH)
Estimates of maximum concentration (Cmax) of ethanol will be calculated and compared from ethanol alone (days 1-2) to concurrent steady state of PT150 with ethanol exposure (days 7-9).
Difference in time of maximum concentration of ethanol (tmaxEtOH)
Estimates of time of maximum concentration (Tmax) of ethanol will be calculated and compared from ethanol alone (days 1-2) to concurrent steady state of PT150 with ethanol exposure (days 7-9).
Difference in terminal elimination half-life of ethanol (t1/2EtOH)
Estimates of terminal elimination half-life (T1/2) of ethanol will be calculated and compared from ethanol alone (days 1-2) to concurrent steady state of PT150 with ethanol exposure (days 7-9).
Difference in the area under the concentration-time curve of ethanol (AUCEtOH)
Estimates of the area under the concentration curve (AUC) through 24 hours post-intervention of ethanol will be calculated and compared from ethanol alone (days 1-2) to concurrent steady state of PT150 with ethanol exposure (days 7-9).
Difference in the number and severity of adverse events
Difference in the overall number and proportion of adverse events compared among ethanol alone (days 1-2), PT150 alone (days 2-7), and PT150 with ethanol exposure (days 7-9). Comparisons will also be stratified by severity of adverse events.
Difference in heart rate
Difference in heart rate compared among ethanol alone (days 1-2), PT150 alone (days 6-7), and PT150 with ethanol exposure (days 7-9).
Difference in systolic blood pressure
Difference in systolic blood pressure compared among ethanol alone (days 1-2), PT150 alone (days 6-7), and PT150 with ethanol exposure (days 7-9).
Difference in diastolic blood pressure
Difference in diastolic blood pressure compared among ethanol alone (days 1-2), PT150 alone (days 6-7), and PT150 with ethanol exposure (days 7-9).
Change in severity of alcohol withdrawal symptom severity as measured on the Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar)
Change in CIWA-Ar total score from baseline (pre-PT150 exposure) to all post-PT150 exposure measurements.
Change in ECG abnormalities
Change in ECG abnormalities from baseline (pre-PT150 exposure) to all post-PT150 exposure measurements.

Full Information

First Posted
March 31, 2020
Last Updated
August 22, 2023
Sponsor
Pop Test Oncology LLC
Collaborators
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance, Congressionally Directed Medical Research Programs, Michael E. DeBakey VA Medical Center, Baylor College of Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT04331288
Brief Title
Effects of Ethanol on the Pharmacokinetics of PT-150 (Formerly ORG34517) (PT150 PK Study)
Official Title
PT150 (Formerly ORG34517) as a Potential Treatment for Alcohol Dependence-Alcohol Interaction Study
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 1, 2021 (Actual)
Primary Completion Date
October 31, 2023 (Anticipated)
Study Completion Date
October 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pop Test Oncology LLC
Collaborators
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance, Congressionally Directed Medical Research Programs, Michael E. DeBakey VA Medical Center, Baylor College of Medicine

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The purpose of this clinical study is to assess pharmacokinetic interactions between ethanol (EtOH) and PT150 (900 mg qd) in non-treatment-seeking alcohol-experienced volunteers-(to include military service members, veterans and/or civilians).
Detailed Description
This study can be classified as a phase 1, single center, and drug-drug interaction (DDI) study. The within-subjects' experimental procedures will assess pharmacokinetic interactions between ethanol (EtOH) and PT150 (900 mg qd) in non-treatment-seeking alcohol-experienced volunteers (to include military service members, veterans and/or civilians). The specific aim of this study is to evaluate the safety and tolerability of PT150 (a novel, selective Glucocorticoid receptor (GR) antagonist) in combination with alcohol and to determine the amount of PT150 and alcohol in blood (i.e., the pharmacokinetic (PK) interactions between alcohol and PT150) in 10 non-treatment seeking participants. The purpose of this study is to assess the possibility of any adverse interactions between alcohol and PT150. While PT150 might be effective in the treatment of AUD, because alcohol can affect the way that PT150 is metabolized in the body, we first need to determine 1) that it is safe to take PT150 in combination with alcohol, and 2) the amount of PT150 and alcohol in blood after PT150 has reached steady state. This study population will be drawn from adults of any race or ethnicity, males, and females who are post-menopausal, undergoing hormone replacement treatment at a stable dosage for at least 3 months, infertile and not hormone cycling, or using approved non-hormonal contraception for at least two weeks after the last dose. Potential enrollees will be drawn of those NOT seeking treatment for alcohol use disorder (AUD). Statistical goals for the study are to evaluate the pharmacokinetics of PT150 given in combination with exposure to alcohol. The primary objective includes assessing if measures of concentration and timing of PT150 levels in the blood differ between the PT150 challenge (challenge on Day 8 and continually observed through Day 9) in combination with alcohol (ethanol beverage) compared to the steady-state PT150 challenge, absent alcohol challenge, on Day 7. Secondary objectives are to determine if measures of concentration and timing of BAL in the blood differ between the active alcohol challenges only (Day 1/baseline) and PT150 challenges in combination with alcohol challenges (Day 8). Other secondary outcomes include evaluating health and safety outcomes as well as withdrawal from alcohol. After completion of the screening period, the remaining study duration will proceed as follows for each participant: Admission for an initial 1-day in-patient stay; Discharge followed by 4 days of outpatient visits; Readmission for a 4-day inpatient stay; and for females, a follow-up visit will be scheduled to occur at least 14 days after the final dose of PT150 is administered to ensure pregnancy has not occurred. This results in a total participant duration of 10 days.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Potential Treatment for Alcohol Dependence-Alcohol Interaction
Keywords
Alcohol, Alcoholic, Alcoholism, Alcohol abuse, Alcohol interaction, Alcohol Use Disorder, Alcohol use, Alcohol dependence, Alcohol dependent, Post Traumatic Stress Disorder, Substance use Disorder, Ethanol abuse, Ethanol use, Pharmacokinetics

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
PT150 with alcohol consumption
Arm Type
Experimental
Arm Description
Study drug to be administered as a single, fixed dose over a 5-day period. An alcohol challenge will be completed on day 1 (pre-treatment) followed by blood draws over a 24-hour period. PT150 dosing will begin on study day 2 and continue until steady state is reached on day 6, at which point blood draws will occur over a 24-hour period. On day 7, after PT150 steady state has been achieved, an alcohol challenge will be completed followed by blood draws over a 40-hour period.
Intervention Type
Drug
Intervention Name(s)
PT150
Other Intervention Name(s)
Formerly ORG34517
Intervention Description
Intervention 1 includes PT150 with alcohol consumption
Intervention Type
Other
Intervention Name(s)
Beverage
Other Intervention Name(s)
Ethanol beverage
Intervention Description
The alcohol beverage will be prepared by an in-house pharmacist at the MEDVAMC in a volume of 450 ml for a 70 kg individual and adjusted for body weight by varying the volume. Alcohol will be administered in a concentration of 16% alcohol (Everclear, St. Louis, MO) by volume in juice or another flavored beverage. Participants will be allowed 30 minutes to consume the beverages.
Primary Outcome Measure Information:
Title
Difference in maximum concentration of PT150 (CmaxPT150)
Description
Estimates of maximum concentration (Cmax) of PT150 will be calculated and compared from PT150 steady state alone (days 6-7) to concurrent steady state of PT150 with ethanol exposure (days 7-9).
Time Frame
from the PT150 blood draws (days 6-7) to the PT150 with concurrent ethanol blood draws (days 7-9)
Title
Difference in time of maximum concentration of PT150 (tmaxPT150)
Description
Estimates of time of maximum concentration (Tmax) of PT150 will be calculated and compared from PT150 steady state alone (days 6-7) to concurrent steady state of PT150 with ethanol exposure (days 7-9).
Time Frame
from the PT150 blood draws (days 6-7) to the PT150 with concurrent ethanol blood draws (days 7-9)
Title
Difference in terminal elimination half-life of PT150 (t1/2PT150)
Description
Estimates of terminal elimination half-life (T1/2) of PT150 will be calculated and compared from PT150 steady state alone (days 6-7) to concurrent steady state of PT150 with ethanol exposure (days 7-9).
Time Frame
from the PT150 blood draws (days 6-7) to the PT150 with concurrent ethanol blood draws (days 7-9)
Title
Difference in area under the concentration-time curve of PT150 (AUCPT150)
Description
Estimates of the area under the concentration curve (AUC) through 24 hours post-intervention of PT150 will be calculated and compared from PT150 steady state alone (days 6-7) to concurrent steady state of PT150 with ethanol exposure (days 7-9).
Time Frame
from the PT150 blood draws (days 6-7) to the PT150 with concurrent ethanol blood draws (days 7-9)
Secondary Outcome Measure Information:
Title
Difference in the maximum concentration of ethanol (CmaxEtOH)
Description
Estimates of maximum concentration (Cmax) of ethanol will be calculated and compared from ethanol alone (days 1-2) to concurrent steady state of PT150 with ethanol exposure (days 7-9).
Time Frame
from the ethanol alone blood draws (days 1-2) to the PT150 with concurrent ethanol blood draws (days 7-9)
Title
Difference in time of maximum concentration of ethanol (tmaxEtOH)
Description
Estimates of time of maximum concentration (Tmax) of ethanol will be calculated and compared from ethanol alone (days 1-2) to concurrent steady state of PT150 with ethanol exposure (days 7-9).
Time Frame
from the ethanol alone blood draws (days 1-2) to the PT150 with concurrent ethanol blood draws (days 7-9)
Title
Difference in terminal elimination half-life of ethanol (t1/2EtOH)
Description
Estimates of terminal elimination half-life (T1/2) of ethanol will be calculated and compared from ethanol alone (days 1-2) to concurrent steady state of PT150 with ethanol exposure (days 7-9).
Time Frame
from the ethanol alone blood draws (days 1-2) to the PT150 with concurrent ethanol blood draws (days 7-9)
Title
Difference in the area under the concentration-time curve of ethanol (AUCEtOH)
Description
Estimates of the area under the concentration curve (AUC) through 24 hours post-intervention of ethanol will be calculated and compared from ethanol alone (days 1-2) to concurrent steady state of PT150 with ethanol exposure (days 7-9).
Time Frame
from the ethanol alone blood draws (days 1-2) to the PT150 with concurrent ethanol blood draws (days 7-9)
Title
Difference in the number and severity of adverse events
Description
Difference in the overall number and proportion of adverse events compared among ethanol alone (days 1-2), PT150 alone (days 2-7), and PT150 with ethanol exposure (days 7-9). Comparisons will also be stratified by severity of adverse events.
Time Frame
Adverse events are reported throughout the study, from enrollment to study completion
Title
Difference in heart rate
Description
Difference in heart rate compared among ethanol alone (days 1-2), PT150 alone (days 6-7), and PT150 with ethanol exposure (days 7-9).
Time Frame
Heart rate is collected one time after the serial blood draws have been completed for each of ethanol alone (day 2), PT150 alone (day 7), and PT150 with ethanol exposure (day 9).
Title
Difference in systolic blood pressure
Description
Difference in systolic blood pressure compared among ethanol alone (days 1-2), PT150 alone (days 6-7), and PT150 with ethanol exposure (days 7-9).
Time Frame
Systolic blood pressure is collected one time after the serial blood draws have been completed for each of ethanol alone (day 2), PT150 alone (day 7), and PT150 with ethanol exposure (day 9).
Title
Difference in diastolic blood pressure
Description
Difference in diastolic blood pressure compared among ethanol alone (days 1-2), PT150 alone (days 6-7), and PT150 with ethanol exposure (days 7-9).
Time Frame
Diastolic blood pressure is collected one time after the serial blood draws have been completed for each of ethanol alone (day 2), PT150 alone (day 7), and PT150 with ethanol exposure (day 9).
Title
Change in severity of alcohol withdrawal symptom severity as measured on the Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar)
Description
Change in CIWA-Ar total score from baseline (pre-PT150 exposure) to all post-PT150 exposure measurements.
Time Frame
The CIWA-Ar assessment is completed one time on day 1 prior to ethanol and PT150 exposure, followed by measurements on days 5, 6, 7, 8, and 9 (all post-PT150 exposure measurements).
Title
Change in ECG abnormalities
Description
Change in ECG abnormalities from baseline (pre-PT150 exposure) to all post-PT150 exposure measurements.
Time Frame
An ECG measurement is taken once on day 1 prior to ethanol and PT150 exposure, followed by measurements on days 2, 5, 6, 7, 8, and 9 (all post-PT150 exposure measurements).

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
64 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Provide signed and dated informed consent form; Male or female, aged 21-64; Must score < 10 on the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar) assessed in the context of a BAL ≤ 0.00% to demonstrate that they do not need medical detoxification; Must have blood lab test results within the acceptable limits noted in the protocol (Tests may be repeated if initial results are out of range); Have normal vitals (heart rate 50-100 bpm, systolic blood pressure 90-140 mmHg and diastolic blood pressure 60-90 mmHg) and a baseline ECG that demonstrates clinically normal sinus rhythm, clinically normal conduction, normal QTc, and no clinically significant arrhythmias; Have a self-reported medical history and brief physical examination demonstrating no clinically significant contraindications for study participation, in the judgment of the admitting physician; Must be willing to comply with all study procedures and be available for the duration of the study; Women must either be unable to conceive (i.e., surgically sterilized, sterile, or post-menopausal) or using non-hormonal, medically acceptable contraception during the study and for at least 2 weeks after the last dose of study drug has been given, with or without additional hormonal contraception. Women can be receiving hormone replacement treatment (HRT) as long as the HRT dose has been stable for a period of at least 3 months; Women must provide a negative urine pregnancy test within 30 days of alcohol administration on Day 1/baseline (i.e. during the screening period) and a negative serum pregnancy test on day 1 prior to alcohol administration and on day 5. Note that because participants are supervised 24-hours a day when they reside as inpatients, a urine pregnancy test is planned on day 9; Able to provide proof of age and identity (includes providing full name and date of birth). Exclusion Criteria: DSM-5 criteria for substance use disorders other than alcohol, nicotine, or marijuana or test positive for prescription or illegal substances other than THC. With regard to marijuana/THC, an individual must agree to abstain from marijuana/THC use three days prior to intake (Day 1/baseline); Be pregnant or nursing; Be receiving HRT where their dose has not been stable for a minimum of 3 months; To reduce variability in the magnitude of drug-drug interactions (DDIs), use of concomitant medications (except hormonal birth control) or OTC medications should be excluded for a sufficient time before subject enrollment (at least 14 days or 5 half-lives [whichever is longer]) and for the entire duration of the study. These items should be excluded for a longer time period if the DDI mechanism is induction or time-dependent inhibition. Concomitant medication use includes any prescription, over-the-counter medications or dietary/herbal/nutritional supplements; Be receiving any non-pharmacotherapy treatments or procedures for which there are precautions for taking concomitantly with PT150 and/or those that might interfere with the study; Have neurological or psychiatric disorders other than AUD or SUD for THC; History of suicide attempts and/or current suicidal ideation/plan; Have evidence of untreated or unstable medical illness including: cardiovascular, neuroendocrine, autoimmune, renal, hepatic, or active HIV+, AIDS infection; Have a history of medically adverse reactions to alcohol (e.g., loss of consciousness (LOC), chest pain, or epileptic seizure) or major alcohol-related medical complications requiring hospitalization (i.e. hepatitis or pancreatitis); Have contraindication(s) to take the study medications such as renal or hepatic impairment, congenital metabolic disorders, or hypersensitivity to study medication class (i.e., glucocorticoid antagonists); Have past brain injury/head trauma with current symptoms (e.g. not photophobic, dizziness, etc.) or past report of LOC for >30 minutes and/or have been blast-exposed or had LOC of >1 minute within the last 10 years and current post-concussive symptoms; Self-report more than thirty days' abstinence from alcohol during the three months prior to enrollment/consent; Current signs of violence or aggression assessed as part of the consent process; Participation in a pharmaceutical trial or exposure to investigational drugs within 1 month of the screening visit; Be currently seeking treatment for AUD; Have any other illness, condition, or use medications (psychotropic or antiretroviral), which in the opinion of the PI and/or the admitting physician would preclude safe and/or successful completion of the study; A history of adrenal insufficiency or a baseline plasma cortisol level of ≤ 5mcg/dL; A baseline cortisol of > 5 mcg/dL BUT a post-ACTH stimulation cortisol of <18 mcg/dL; Have been treated with any form of corticosteroid in the past 30 days; Have a history of endometrial hyperplasia, endometrial cancer, uterine polyps, or unexplained vaginal bleeding; Have potassium levels below the normal reference range; Men taking testosterone replacement therapy; Men or women currently interested in fertility; Have underlying inflammatory or auto-immune disorders; Have elevated thyroid stimulating hormone (TSH) levels; Have Type I diabetes.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Christopher Verrico, PhD
Phone
713-791-1414
Ext
26020
Email
verrico@bcm.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Thomas Kosten, MD
Phone
(713) 794-7032
Email
kosten@bcm.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christopher Verrico, PhD
Organizational Affiliation
Michael E. DeBakey Veterans Affairs Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Michael E. DeBakey Veterans Affairs Medical Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christopher Verrico, PhD
Phone
713-791-1414
Ext
26020
Email
verrico@bcm.edu
First Name & Middle Initial & Last Name & Degree
Thomas Kosten, MD
Phone
(713) 794-7032
Email
kosten@bcm.edu
First Name & Middle Initial & Last Name & Degree
Christopher Verrico, PhD

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Data will be shared with a registry per the data sharing plans of the Consortium
Links:
URL
https://pasa.rti.org/
Description
Related Info

Learn more about this trial

Effects of Ethanol on the Pharmacokinetics of PT-150 (Formerly ORG34517) (PT150 PK Study)

We'll reach out to this number within 24 hrs